Global Congenital Neutropenia Treatment Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 15.03 Million |
 Market Size (Forecast Year) |
USD 23.77 Million |
 CAGR |
% |
| Major Markets Players |
>全球先天性中性粒细胞减少症治疗市场，按类型（特发性、周期性、自身免疫性中性粒细胞减少症）、治疗（抗生素疗法、集落刺激因子疗法、粒细胞输血、脾切除术等）、给药途径（租赁、其他）、最终用户（医院、家庭护理、专科中心、其他）、分销渠道（医院药房、网上药房、零售药房）划分 - 行业趋势和预测到 2030 年。
先天性中性粒细胞减少症治疗市场分析及规模
预测期内，先天性中性粒细胞减少症治疗市场预计将出现显著增长。2014 年，美国登记了约 160 万例新发癌症病例，约 60 万人死亡。市场主要受癌症高发性（化疗是主要治疗方法）和多种有前景的药物研发的推动。多种治疗方案和有效诊断被视为先天性中性粒细胞减少症治疗市场增长需求的积极指标。
Data Bridge Market Research 分析了 2023-2030 年预测期内全球先天性中性粒细胞减少症治疗市场的增长率。在上述预测期内，全球先天性中性粒细胞减少症治疗市场的预期复合年增长率约为 5.90%。2022 年市场价值为 1503 万美元，到 2030 年将增长至 2377 万美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。
先天性中性粒细胞减少症治疗市场范围和细分
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021（可定制为 2015 - 2020） |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
类型（特发性、周期性、自身免疫性中性粒细胞减少症）、治疗方法（抗生素疗法、集落刺激因子疗法、粒细胞输血、脾切除术等）、给药途径（口服、肠胃外、其他）、最终用户（医院、家庭护理、专科中心、其他）、分销渠道（医院药房、网上药房、零售药房） |
|
覆盖国家 |
U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Amgen Inc. (U.S.), Boehringer Ingelheim International GmbH. (Germany), Ipsen Pharma (France), Spectrum Pharmaceuticals, Inc. (U.S.), Takeda Pharmaceutical Company Limited. (Japan)., BeyondSpring Inc. (U.S.)., Myelo Therapeutics GmbH (Germany)., Sandoz International GmbH (Switzerland), BioGenomics Limited. (India), Dr. Reddy's Laboratories Ltd. (India), Apotex Inc. (Canada) |
|
Market Opportunities |
|
Market Definition
Neutropenia is a rare disease in which a sudden decline in the level of neutrophils is witnessed, resulting in compromised immunity. Neutropenia can either be caused by several diseases or conditions such as chemotherapy, several infections, congenital bone marrow disorders, or autoimmune disorders, and also through specific drugs.
Global Congenital Neutropenia Treatment Market Dynamics
Drivers
- Increasing Demand for Targeted Therapy
The increasing demand for targeted therapy showed numerous advantages as it interferes with specific proteins involved in cancer, focusing on specific molecular changes that stop the growth of several cancers. Numerous major factors influenced the growth of uterine cancer, including the fewer adverse effects of the therapy and the availability of several targeted therapeutics. This boosts market growth.
- Growing R&D Activities
The latest introduction of small molecules is one of the major technologies that is gaining attraction globally in the market. The development of Plinabulin, a tiny chemical with immune-boosting properties created by BeyondSpring Pharmaceuticals, is projected to transform neutropenia treatment. In addition, Phase II tests have shown that this chemical has even more effective anti-cancer properties. This boosts market growth.
Opportunities
- Increase in Cancer Cases
The increasing occurrence of cancer is boosting the growth of the market. The frequency of patients with cancer in India among males was 679,421, and that for females was 712,758 for the year 2020. Cancer is a known cause of developing neutropenia. The primary treatment for cancer is chemotherapy and neutropenia can be caused by the extensive application of chemotherapy to the patients. Thus, it boosts market growth.
- Rising Healthcare Awareness
人们的健康意识正在增强，因此人们预测药物将推动市场增长。这一大幅增长归因于前景光明的治疗渠道，其中包括约五种用于治疗中性粒细胞减少症的 III 期临床研究药物。随着白血病发病率的上升（主要是在治疗后），中性粒细胞减少症的风险预计会增加。这为市场创造了更多机会。
限制/挑战
- 化疗的副作用
化疗会产生多种副作用。贫血、口腔溃疡、脱发、感染和疲劳等副作用深深影响着患者，从而阻碍了市场的增长。
- 高成本将阻碍经济增长
治疗方法的巨额支出阻碍了市场的增长。通常，由于缺乏适当的付款计划和组织的特殊考虑，患者无法适应这些高端治疗方案，从而损害了他们的健康。因此，这是一个需要注意的重要限制。
这份全球先天性中性粒细胞减少症治疗市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响，分析了新兴收入领域的机会、市场法规的变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新。如需了解有关全球先天性中性粒细胞减少症治疗市场的更多信息，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您做出明智的市场决策，实现市场增长。
全球先天性中性粒细胞减少症治疗市场范围
全球先天性中性粒细胞减少症治疗市场根据类型、治疗、给药途径、分销渠道和最终用户进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
类型
- 特发性
- 循环
- 自身免疫性中性粒细胞减少症
治疗
- 抗生素 治疗
- 集落刺激因子疗法
- 粒细胞输注
- 脾切除术
- 其他的
给药途径
- 口服
- 肠外
- 其他的
最终用户
- 医院
- 家庭护理
- 专业中心
- 其他的
分销渠道
- 医院药房
- 网上药店
- 零售药店
先天性中性粒细胞减少症治疗市场区域分析/见解
对全球先天性中性粒细胞减少症治疗市场进行了分析，并按类型、治疗、给药途径、分销渠道和最终用户提供了市场规模洞察和趋势。
全球先天性中性粒细胞减少症治疗市场报告涉及的主要国家 包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。
由于医疗保健基础设施良好、人均收入高、先进手术采用率高，预计北美将拥有最高的市场增长
由于大力推广研发活动和提高人们对该疾病的认识，亚太地区占据了市场主导地位。此外，大量白血病病例和接受一线化疗的相关患者也推动了该地区的市场增长。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
竞争格局和全球先天性中性粒细胞减少症治疗市场份额分析
全球先天性中性粒细胞减少症治疗市场竞争格局提供了按竞争对手划分的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对全球先天性中性粒细胞减少症治疗市场的关注有关。
全球先天性中性粒细胞减少症治疗市场的主要参与者包括：
- 安进公司 (美国)
- 勃林格殷格翰国际有限公司（德国）
- 益普生制药（法国）
- Spectrum Pharmaceuticals, Inc.（美国）
- 武田药品工业株式会社（日本）
- BeyondSpring Inc.（美国）。
- Myelo Therapeutics GmbH（德国）
- Sandoz International GmbH（瑞士）
- BioGenomics Limited.（印度）
- Dr. Reddy's Laboratories Ltd.（印度）
- Apotex Inc.（加拿大）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
